Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Hepatitis B Virus (HBV) Capsid Inhibitors Global Market Report 2025
Download Free Sample Buy Now
Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Report 2025

Report Price : $4490.00

Pages : 250

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Hepatitis B Virus (HBV) Capsid Inhibitors Global Market Report 2025

By Drug Type (Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types), By Application (Chronic Hepatitis B, Acute Hepatitis B, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels), By End-User (Hospitals, Clinics, Research Institutes, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

• Hepatitis B Virus (HBV) Capsid Inhibitors market size has reached to $0.46 billion in 2024

• Expected to grow to $0.86 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%

• Growth Driver: Surge In Hepatitis B Virus (HBV) Infections Fueling The Growth Of The Market Due To Low Vaccination Coverage

• Market Trend: Advancements In HBV Capsid Inhibitors Development

• Asia-Pacific was the largest region in 2024.

What Is Covered Under Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Hepatitis B virus (HBV) capsid inhibitors refer to a class of antiviral agents designed to disrupt the assembly, disassembly, or stability of the viral capsid, which is essential for HBV replication. These inhibitors target the core protein responsible for forming the protective shell around the viral DNA, thereby preventing the production of new infectious particles. By interfering with the capsid formation process, they help reduce viral load and disease progression. HBV capsid inhibitors represent a promising therapeutic approach for achieving a functional cure in chronic hepatitis b infection.

The main drug types of hepatitis B virus (HBV) capsid inhibitors are core protein allosteric modulators (CpAMs), capsid assembly modulators, and others. hepatitis B virus (HBV) capsid inhibitors, also known as core protein allosteric modulators (CpAMs), are antiviral agents that target and disrupt the assembly or stability of the viral capsid, thereby blocking HBV replication and reducing viral activity. The applications involved are chronic hepatitis B, acute hepatitis B, and other applications, and are distributed using hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. The end users include hospitals, clinics, research institutes, and others.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Size and growth rate 2025 to 2029: Graph

What Is The Hepatitis B Virus (HBV) Capsid Inhibitors Market Size 2025 And Growth Rate?

The hepatitis B virus (HBV) capsid inhibitors market size has grown rapidly in recent years. It will grow from $0.46 billion in 2024 to $0.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to increasing clinical trials focused on HBV capsid assembly modulators, rising inclusion of HBV in national immunization and health surveillance programs, growing publication of clinical data validating capsid inhibitor efficacy, rising global awareness campaigns promoting HBV prevention and management, and increasing adoption of advanced molecular modeling and drug design technologies.

What Is The Hepatitis B Virus (HBV) Capsid Inhibitors Market Growth Forecast?

The hepatitis B virus (HBV) capsid inhibitors market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growth in demand for combination therapies, an increase in pipeline products entering advanced clinical trial phases, a rise in patient awareness and screening rates for chronic HBV infection, a rise in adoption of personalized treatment approaches targeting viral resistance, and growth in the use of digital platforms for clinical monitoring and treatment adherence. Major trends in the forecast period include the advancement of next-gen capsid assembly modulators progressing through clinical trials, advanced combination regimens pairing capsid inhibitors with immune modulators and cccDNA-targeting agents, innovative oral small-molecule formulations improving patient adherence, integration of biomarkers and companion diagnostics to guide therapy selection, and advancement of strategies to manage and prevent resistance, including next-gen molecules.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Hepatitis B Virus (HBV) Capsid Inhibitors Market Segmented?

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

What Is Driving The Hepatitis B Virus (HBV) Capsid Inhibitors Market? Surge In Hepatitis B Virus (HBV) Infections Fueling The Growth Of The Market Due To Low Vaccination Coverage

The increasing prevalence of hepatitis B virus infections is expected to propel the growth of the hepatitis B virus (HBV) capsid inhibitors market going forward. Hepatitis B Virus (HBV) infections refer to liver infections caused by the hepatitis B virus that can lead to both acute and chronic diseases, spreading through contact with infected blood or bodily fluids and resulting in serious complications such as liver cirrhosis or liver cancer. The increasing prevalence of Hepatitis B Virus (HBV) infections is mainly due to low vaccination coverage, which leaves large portions of the population unprotected and allows the virus to spread more easily through contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors help hepatitis B virus (HBV) infections by disrupting the formation and assembly of the viral capsid, thereby preventing viral replication and reducing the spread of infection within the body. For instance, in April 2024, according to a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, as of the end of 2022, only 13% of individuals with chronic hepatitis B had been diagnosed, and approximately 3% (7 million) had received antiviral treatment. For hepatitis C, 36% of affected individuals had been diagnosed, with 20% (12.5 million) receiving curative therapy, figures that remain far below the global target of treating 80% of people living with chronic hepatitis B and C by 2030. Therefore, the increasing prevalence of hepatitis B virus infections is driving the growth of the hepatitis B virus (HBV) capsid inhibitors industry.

Who Are The Major Players In The Global Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

What Are The Key Trends Of The Global Hepatitis B Virus (HBV) Capsid Inhibitors Market? Advancements In HBV Capsid Inhibitors Development

Major companies operating in the hepatitis B virus (HBV) capsid inhibitors market are focusing on developing advancements such as oral small molecule capsid assembly modulators to enhance antiviral efficacy, improve patient compliance, and achieve sustained viral suppression. Oral small-molecule capsid assembly modulators refer to orally administered antiviral agents that interfere with the assembly of the hepatitis B virus (HBV) capsid, blocking its replication and reducing viral activity in the body. For instance, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to launch a clinical trial to evaluate innovative treatment candidates for chronic hepatitis B (CHB), aiming to leverage its advanced capsid assembly modulator technology to enhance antiviral efficacy and accelerate the development of next-generation HBV therapies. The launch marks a significant step in advancing Aligos’s mission to develop effective and potentially curative treatments for patients suffering from chronic hepatitis B.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Hepatitis B Virus (HBV) Capsid Inhibitors Market? Gilead Sciences And Assembly Biosciences Partner To Advance HBV Therapies

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to leverage its antiviral expertise alongside Assembly Biosciences Inc.’s innovative capsid inhibitor technology to accelerate the development of next-generation small-molecule antivirals that enhance viral suppression, improve treatment outcomes, and potentially achieve a functional cure for patients living with chronic hepatitis B infection. Assembly Biosciences Inc. is a US-based biotechnology company specializing in the discovery and development of antiviral therapeutics, including novel agents targeting the hepatitis B virus (HBV) and other viral infections.

What Is The Regional Outlook For The Global Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hepatitis B Virus (HBV) Capsid Inhibitors Market?

The hepatitis B virus (HBV) capsid inhibitors market consists of sales of vebicorvir, bepirovirsen, cavrotolimod, hepcludex, and morphothiadin. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Hepatitis B Virus (HBV) Capsid Inhibitors Industry?

The hepatitis b virus (hbv) capsid inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis b virus (hbv) capsid inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $0.52 billion
Revenue Forecast In 2034 $0.86 billion
Growth Rate CAGR of 13.8% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered Drug Type, Application, Distribution Channel, End-User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Hepatitis B Virus (HBV) Capsid Inhibitors Market Characteristics

3. Hepatitis B Virus (HBV) Capsid Inhibitors Market Trends And Strategies

4. Hepatitis B Virus (HBV) Capsid Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Hepatitis B Virus (HBV) Capsid Inhibitors Growth Analysis And Strategic Analysis Framework

5.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Growth Rate Analysis

5.4. Global Hepatitis B Virus (HBV) Capsid Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Hepatitis B Virus (HBV) Capsid Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Hepatitis B Virus (HBV) Capsid Inhibitors Total Addressable Market (TAM)

6. Hepatitis B Virus (HBV) Capsid Inhibitors Market Segmentation

6.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Core Protein Allosteric Modulators (CpAMs)

Capsid Assembly Modulators

Other Drug Types

6.2. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chronic Hepatitis B

Acute Hepatitis B

Other Applications

6.3. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other Distribution Channels

6.4. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Research Institutes

Other End-Users

6.5. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Core Protein Allosteric Modulators (CpAMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Class I Core Protein Allosteric Modulators (CpAMs)

Class II Core Protein Allosteric Modulators (CpAMs)

6.6. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Capsid Assembly Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Direct Capsid Assembly Modulators

Indirect Capsid Assembly Modulators

6.7. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Novel Capsid Inhibitors

Combination Therapies

Experimental Mechanism-Based Inhibitors

7. Hepatitis B Virus (HBV) Capsid Inhibitors Market Regional And Country Analysis

7.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market

8.1. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis B Virus (HBV) Capsid Inhibitors Market

9.1. China Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

9.2. China Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis B Virus (HBV) Capsid Inhibitors Market

10.1. India Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market

11.1. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

11.2. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market

12.1. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market

13.1. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market

14.1. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

14.2. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market

15.1. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

15.2. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market

16.1. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market

17.1. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis B Virus (HBV) Capsid Inhibitors Market

18.1. France Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market

19.1. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market

20.1. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market

21.1. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

21.2. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market

22.1. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market

23.1. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

23.2. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market

24.1. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

24.2. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market

25.1. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

25.2. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market

26.1. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

26.2. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market

27.1. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market

28.1. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

28.2. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market

29.1. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview

29.2. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Landscape And Company Profiles

30.1. Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Landscape

30.2. Hepatitis B Virus (HBV) Capsid Inhibitors Market Company Profiles

30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Jiangsu Hengrui Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis B Virus (HBV) Capsid Inhibitors Market Other Major And Innovative Companies

31.1. Novotech Health Holdings Pte. Ltd

31.2. Enanta Pharmaceuticals Inc.

31.3. Assembly Biosciences Inc.

31.4. Arbutus Biopharma Corporation

31.5. Aligos Therapeutics Inc.

31.6. Qilu Pharmaceutical Co Ltd.

31.7. Chia Tai Tianqing Pharmaceutical Group Co Ltd.

31.8. Hepion Pharmaceuticals Inc.

31.9. Shanghai Zhimeng Biopharma Inc.

31.10. Antios Therapeutics

31.11. Bluejay Therapeutics Inc.

31.12. Core Biopharma Inc.

31.13. Door Pharmaceuticals

31.14. Shanghai Longwood Biopharmaceuticals Co. Ltd.

31.15. Zhimeng Biopharma Inc.

32. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis B Virus (HBV) Capsid Inhibitors Market

34. Recent Developments In The Hepatitis B Virus (HBV) Capsid Inhibitors Market

35. Hepatitis B Virus (HBV) Capsid Inhibitors Market High Potential Countries, Segments and Strategies

35.1 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2029 - Countries Offering Most New Opportunities

35.2 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2029 - Segments Offering Most New Opportunities

35.3 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Core Protein Allosteric Modulators (CpAMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Capsid Assembly Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Johnson & Johnson Financial Performance
  • Table 79: Roche Holding AG Financial Performance
  • Table 80: GlaxoSmithKline plc Financial Performance
  • Table 81: Gilead Sciences Inc. Financial Performance
  • Table 82: Jiangsu Hengrui Pharmaceuticals Co. Ltd. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Core Protein Allosteric Modulators (CpAMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Capsid Assembly Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Johnson & Johnson Financial Performance
  • Figure 79: Roche Holding AG Financial Performance
  • Figure 80: GlaxoSmithKline plc Financial Performance
  • Figure 81: Gilead Sciences Inc. Financial Performance
  • Figure 82: Jiangsu Hengrui Pharmaceuticals Co. Ltd. Financial Performance

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Read More About Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

Read More About Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

$8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Read More About $8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

Read More About Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the MSI-H and DMMR Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the MSI-H and DMMR Market with 2025 insights from The Business Research Company.

Hepatitis B Virus (HBV) Global Market Report 2025 – By Type (Acute, Chronic), By Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccine, Surgery), By Age Group (Pediatrics, Adults, Seniors), By End User (Medical Pro...

View Report

Preventive Vaccines Global Market Report 2025 - By Type (Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines), By Disease Ty...

View Report

Chronic Hepatitis B Global Market Report 2025 – By Drug Class (Antivirals, Immune Modulators), By Gender (Male, Female), By Distribution Channel (Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers) ...

View Report

Hepatitis Therapeutics Global Market Report 2025 – By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types), By Drug Class (Oral Antivirals, Immune Modulators), By Distribution Channel (Hospital Pharm...

View Report

Hepatitis Drugs Global Market Report 2025 – By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Po...

View Report

Viral Hepatitis Global Market Report 2025 – By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types), By Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis), By Treatment (Antiviral ...

View Report

Antiviral Combination Therapy Global Market Report 2025 – By Type (Branded, Generic), By Drug Combination (Nucleotide Reverse Transcriptase Inhibitors/Non-Nucleotide Reverse Transcriptase Inhibitors, Integrase Inhibitor/...

View Report

Alcoholic Hepatitis Treatment Global Market Report 2025 – By Treatment (Drug Treatment, Stem Cell Therapy), By Drug Class (Corticosteroids, Hemorheologic Agents, Monoclonal Antibodies, Anabolic Steroids, Other Drug Class...

View Report

Frequently Asked Questions

Hepatitis B virus (HBV) capsid inhibitors refer to a class of antiviral agents designed to disrupt the assembly, disassembly, or stability of the viral capsid, which is essential for HBV replication. These inhibitors target the core protein responsible for forming the protective shell around the viral DNA, thereby preventing the production of new infectious particles. By interfering with the capsid formation process, they help reduce viral load and disease progression. HBV capsid inhibitors represent a promising therapeutic approach for achieving a functional cure in chronic hepatitis B infection. For further insights on this market, request a sample here

The market major growth driver - Surge In Hepatitis B Virus (HBV) Infections Fueling The Growth Of The Market Due To Low Vaccination Coverage. For further insights on this market, request a sample here

The hepatitis B virus (HBV) capsid inhibitors market size has grown rapidly in recent years. It will grow from $0.46 billion in 2024 to $0.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to increasing clinical trials focused on HBV capsid assembly modulators, rising inclusion of HBV in national immunization and health surveillance programs, growing publication of clinical data validating capsid inhibitor efficacy, rising global awareness campaigns promoting HBV prevention and management, and increasing adoption of advanced molecular modeling and drug design technologies. The hepatitis B virus (HBV) capsid inhibitors market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growth in demand for combination therapies, an increase in pipeline products entering advanced clinical trial phases, a rise in patient awareness and screening rates for chronic HBV infection, a rise in adoption of personalized treatment approaches targeting viral resistance, and growth in the use of digital platforms for clinical monitoring and treatment adherence. Major trends in the forecast period include the advancement of next-gen capsid assembly modulators progressing through clinical trials, advanced combination regimens pairing capsid inhibitors with immune modulators and cccDNA-targeting agents, innovative oral small-molecule formulations improving patient adherence, integration of biomarkers and companion diagnostics to guide therapy selection, and advancement of strategies to manage and prevent resistance, including next-gen molecules. For further insights on this market, request a sample here

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –
1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types
2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users Subsegments:
1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)
2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators
3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors For further insights on this market, request a sample here

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2024. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc. . For further insights on this market, request a sample here.

Major trends in this market include Advancements In HBV Capsid Inhibitors Development. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon